Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

The emerging role of the endocannabinoid system in cardiovascular disease.

Pacher P, Steffens S.

Semin Immunopathol. 2009 Jun;31(1):63-77. doi: 10.1007/s00281-009-0145-8. Epub 2009 Apr 9. Review.

2.

Endocannabinoids in liver disease.

Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G.

Hepatology. 2011 Jan;53(1):346-55. doi: 10.1002/hep.24077. Review.

3.

Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Pacher P, Haskó G.

Br J Pharmacol. 2008 Jan;153(2):252-62. Epub 2007 Nov 19. Review.

4.

The endocannabinoid system as an emerging target of pharmacotherapy.

Pacher P, Bátkai S, Kunos G.

Pharmacol Rev. 2006 Sep;58(3):389-462. Review.

5.

Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases.

Pacher P, Gao B.

Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G850-4. doi: 10.1152/ajpgi.00523.2007. Epub 2008 Jan 31. Review.

6.

Endocannabinoids and cardiac contractile function: pathophysiological implications.

Bátkai S, Pacher P.

Pharmacol Res. 2009 Aug;60(2):99-106. Review.

7.
9.

Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.

Vemuri VK, Janero DR, Makriyannis A.

Physiol Behav. 2008 Mar 18;93(4-5):671-86. Epub 2007 Nov 21. Review.

10.

Endocannabinoid system: An overview of its potential in current medical practice.

Mouslech Z, Valla V.

Neuro Endocrinol Lett. 2009;30(2):153-79. Review.

PMID:
19675519
11.

Altered endocannabinoid signalling after a high-fat diet in Apoe(-/-) mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance.

Bartelt A, Orlando P, Mele C, Ligresti A, Toedter K, Scheja L, Heeren J, Di Marzo V.

Diabetologia. 2011 Nov;54(11):2900-10. doi: 10.1007/s00125-011-2274-6. Epub 2011 Aug 17.

PMID:
21847582
12.

The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings.

Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S.

Br J Pharmacol. 2011 Aug;163(7):1432-40. doi: 10.1111/j.1476-5381.2011.01397.x. Review.

13.

Is lipid signaling through cannabinoid 2 receptors part of a protective system?

Pacher P, Mechoulam R.

Prog Lipid Res. 2011 Apr;50(2):193-211. doi: 10.1016/j.plipres.2011.01.001. Epub 2011 Feb 2. Review.

14.

The endocannabinoid system and cardiometabolic risk.

Szmitko PE, Verma S.

Atherosclerosis. 2008 Aug;199(2):248-56. doi: 10.1016/j.atherosclerosis.2008.03.011. Epub 2008 Mar 20. Review.

PMID:
18440538
15.

Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy.

Rajesh M, Bátkai S, Kechrid M, Mukhopadhyay P, Lee WS, Horváth B, Holovac E, Cinar R, Liaudet L, Mackie K, Haskó G, Pacher P.

Diabetes. 2012 Mar;61(3):716-27. doi: 10.2337/db11-0477. Epub 2012 Feb 7.

16.

The endocannabinoid system and liver diseases.

Caraceni P, Domenicali M, Bernardi M.

J Neuroendocrinol. 2008 May;20 Suppl 1:47-52. doi: 10.1111/j.1365-2826.2008.01679.x. Review.

PMID:
18426499
17.

Dysregulation of the endocannabinoid system in obesity.

Engeli S.

J Neuroendocrinol. 2008 May;20 Suppl 1:110-5. doi: 10.1111/j.1365-2826.2008.01683.x. Review.

PMID:
18426509
18.

New vistas for treatment of obesity and diabetes? Endocannabinoid signalling and metabolism in the modulation of energy balance.

Lipina C, Rastedt W, Irving AJ, Hundal HS.

Bioessays. 2012 Aug;34(8):681-91. doi: 10.1002/bies.201200031. Epub 2012 Jun 5. Review.

PMID:
22674489
19.

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.

Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L, Wang L, Kunos G.

J Clin Invest. 2005 May;115(5):1298-305.

20.

Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders.

Bisogno T, Di Marzo V.

CNS Neurol Disord Drug Targets. 2010 Nov;9(5):564-73. Review.

PMID:
20632970
Items per page

Supplemental Content

Write to the Help Desk